Competing, bespoke CAR-T cell therapies from Gilead Sciences and Bristol Myers Squibb have each demonstrated additional benefit for patients with B-cell lymphoma at an earlier stage of treatment than they’re used for currently. But is one better than the other?
Results from the successful clinical trials, dubbed ZUMA-7 and TRANSFORM by Gilead and Bristol, respectively, are being presented this weekend at the annual meeting of the American Society of Hematology. Collectively, the data are likely to expand the use of these CAR-T therapies — Gilead’s Yescarta and Bristol’s Breyanzi — and deliver larger sales for both companies.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
